Compare Crispr Therapeutics AG (CRSP) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Palo Alto Networks Inc — how do they compare? Crispr Therapeutics AG trades at $53.8 (market cap $5.23B), while Palo Alto Networks Inc trades at $384.39 (market cap $312.80B). The key difference: Palo Alto Networks Inc is far larger — about 59.8× Crispr Therapeutics AG's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | PANW | |
|---|---|---|
Market Cap | $5.23B | $312.80B |
Sector | Health | Technology |
52-Week High | $76.78 | $385.04 |
52-Week Low | $44.34 | $141.67 |
Enterprise Value | $3.65B | $311.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Palo Alto Networks (PANW) trades at $385.04, up 5.82% over the past day, reflecting strong momentum amid positive sentiment around AI-driven cybersecurity demand. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, while RSI levels suggest potential overbought conditions. Fundamentally, the company reported revenue of $9.22B in 2025 with a net income margin of 7.95%, though valuation ratios like P/E of 333.74 indicate a premium. Recent news highlights record highs following the Black Hat conference and AI platform launches, though a Chinese regulatory review introduces near-term uncertainty.
The outlook for PANW remains positive given robust revenue growth, AI integration, and Wall Street's bullish consensus, but risks include elevated valuation, integration costs from acquisitions, and geopolitical scrutiny. Investors should weigh the company's leadership in cybersecurity against potential volatility from regulatory developments and high expectations priced into the stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
